Drug Discovery World

MAY 30, 2024

KP: Our research is conducted by a multidisciplinary team of clinicians, scientists, and research nurses, and is a collaboration of different research sites with specialist facilities. Responses to vaccines are not equal across different subtypes of flu, different variants of SARS-CoV-2 and in different patient groups however.

Vaccine 147

Vaccine Protein Expression Clinical Trials Immune Response 147

The Pharma Data

DECEMBER 29, 2020

29, 2020 /PRNewswire/ — Phase 3 program in hospitalized patients to continue based on passing futility analysis on ability to reduce incidence of death or mechanical ventilation. As in earlier outpatient trial, immune status when patients entered the trial was a strong predictor of viral load and clinical outcomes.

Hospitals 52

Hospitals Trials Clinical Trials Production 52

The Pharma Data

DECEMBER 9, 2020

In the new study, researchers found that among COVID patients at their safety-net hospital, neurological complications ran the gamut. Safety-net hospitals are obligated, by mandate or mission, to treat people regardless of their ability to pay. In her study group, 10 patients died in the hospital. ” © 2020 HealthDay.

Hospitals 52

Hospitals Doctors Immune Response Nurses 52

The Pharma Data

DECEMBER 17, 2020

(NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. “The investigational cocktail is now available to indicated high-risk U.S.

Hospitals 52

Hospitals Production Clinical Trials Virus 52

The Pharma Data

NOVEMBER 19, 2020

A study out of Rutgers University found that healthcare staffers, especially nurses, have a higher prevalence of COVID-19 than non-healthcare workers. The study data came from a prospective study of participants at Rutgers and affiliated hospitals during the early phase of the pandemic. Healthcare Workers Most at Risk for COVID-19.

Research 52

Research Nurses Disease Immune Response 52

The Pharma Data

NOVEMBER 20, 2020

The clinical evidence from Regeneron’s outpatient trial suggests that monoclonal antibodies such as casirivimab and imdevimab have the greatest benefit when given early after diagnosis and in patients who have not yet mounted their own immune response or who have high viral load. Limitations of Authorized Use.

Therapies 52

Therapies FDA Clinical Trials Hospitals 52

The Pharma Data

NOVEMBER 21, 2020

The clinical evidence from Regeneron’s outpatient trial suggests that monoclonal antibodies such as REGEN-COV2 have the greatest benefit when given early after diagnosis and in patients who have not yet mounted their own immune response or who have high viral load. Limitations of Authorized Use.

FDA 40

FDA Clinical Trials Hospitals Government 40